Login to Your Account



Celyad shares drop 40% on cell therapy phase III miss in heart failure

By Cormac Sheridan
Staff Writer

Tuesday, June 28, 2016

DUBLIN – Shares in Celyad SA fell 40 percent in Brussels Tuesday on news that its C-Cure stem cell therapy failed to reach the primary endpoint of a phase III trial in patients with congestive heart failure.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription